Nanobiotechnology-based drug delivery to the central nervous system

Neurodegenerative Diseases

Volumn 4, Issue 4, 2007, Pages 287-291

  Jain, K K ^a,b  

^a JAIN PHARMABIOTECH   (Switzerland)

^b NONE   (Switzerland)

Author keywords

Blood brain barrier; Central nervous system; Drug delivery; Liposomes; Nanobiotechnology; Nanoparticles; Nanotechnology

Indexed keywords

LIPOSOME; NANOPARTICLE; NEUROIMMUNOPHILIN; POLYMER;

BLOOD BRAIN BARRIER; CATHETER; CELL LEVEL; CENTRAL NERVOUS SYSTEM; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TRANSPORT; GENE DELIVERY SYSTEM; GENE THERAPY; INHIBITION KINETICS; LIPID SOLUBILITY; NANOBIOTECHNOLOGY; NANOFLUIDICS; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY;

EID: 34347402058     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000101884     Document Type: Review

References (17)

1. Jain KK: Drug Delivery in Central Nervous System Disorders. Basel, Jain PharmaBiotech Publications, 2007.
2. Sziraki I, Horvath K, Bodor N: Comparative evaluation of Estredox, a brain-targeted estradiol delivery system versus traditional estrogen replacement therapy. Pharmazie 2006;61:140-143.
3. Jain KK: Nanobiotechnology. Basel, Jain PharmaBiotech Publications, 2007.
4. Tiwari SB, Amiji MM: A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006;3:219-232.
5. Aliautdin RN, Kreuter J, Kharkevich DA: Drug delivery to the brain with nanoparticles. Eksp Klin Farmakol 2003;66:65-68.
6. Kreuter J, Shamenkov D, Petrov V, et al: Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002;10:317-325.
7. Kreuter J, Ramge P, Petrov V, et al: Direct evidence that polysorbate-80-coated poly-(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003;20:409-416.
8. Michaelis K, Hoffmann MM, Dreis S, et al: Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006;317:1246-1253.
9. Costantino L, Gandolfi F, Tosi G, et al: Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release 2005;108:84-96.
10. Xie Y, Ye L, Zhang X, et al: Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J Control Release 2005;105:106-119.
11. Visser CC, Stevanovic S, Voorwinden LH, et al: Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur J Pharm Sci 2005;25:299-305.
12. Bharali DJ, Klejbor I, Stachowiak EK, et al: Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci USA 2005;102:11539-11544.
13. McKenzie JL, Waid MC, Shi R, Webster TJ: Decreased functions of astrocytes on carbon nanofiber materials. Biomaterials 2004;25:1309-1317.
14. Kam NW, Dai H: Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J Am Chem Soc 2005;127:6021-6026.
15. Peters A, Veronesi B, Calderon-Garciduenas L, et al: Translocation and potential neurological effects of fine and ultrafine particles: a critical update. Part Fibre Toxicol 2006;3:13. DOI:10.1186/1743-8977-3-13.
16. Sayes CM, Gobin AM, Ausman KD, et al: Nano-C(60) cytotoxicity is due to lipid peroxidation. Biomaterials 2005;26:7587-7595.
17. Jain KK: Role of nanotechnology in developing new therapies for diseases of the nervous system. Nanomedicine 2006;1:9-12.